T cell defined tumor antigens
Current Opinion in ImmunologyPublished 1 October 1997
Benoı̂t J. Van den Eynde, Pierre van der Bruggen
Citations624
SJR quartileQ1
SJR score2.74
SNIP1.38
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The priority is now to demonstrate that immunization against some of these antigens is clinically valuable for antitumor therapy, and the first results of clinical pilot studies are now emerging.
Abstract
T cell defined antigens have now been characterized in a large variety of tumor types, in both mice and humans. An increasing number of these antigens appear to result from tumor-specific mutations, and some of these mutations may be implicated in oncogenesis. The priority is now to demonstrate that immunization against some of these antigens is clinically valuable for antitumor therapy, and the first results of clinical pilot studies are now emerging.
Keywords
Immunology and MicrobiologyMedicine
CellFLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex
3,060 Citations1996Marta Muzio, Arul M. Chinnaiyan +12 more
This work utilized nano-electrospray tandem mass spectrometry to identify CAP3 and CAP4, components of the CD95 (Fas/APO-1) death-inducing signaling complex, and found a novel 55 kDa protein, designated FLICE, which has homology to both FADD and the ICE/CED-3 family of cysteine proteases.
CellInvolvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death
2,301 Citations1996Mark Boldin, Tanya Goncharov +2 more
This work cloned a novel protein, MACH, that binds to MORT1, and suggests that MACH is the most upstream enzymatic component in the Fas/APO-1- and p55-R-induced cell death signaling cascades.
Nature MedicineVaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
1,839 Citations1996Frank J. Hsu, Claudia Benike +6 more
This pilot study investigated the ability of autologous dendritic cells pulsed ex vivo with tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a vaccine in patients with follicular B–cell lymphoma.
ScienceStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
1,219 Citations1997Bonnee Rubinfeld, Paul F. Robbins +4 more
Genetic defects that result in up-regulation of β-catenin may play a role in melanoma progression.
ScienceA p16 <sup>INK4a</sup> -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
1,149 Citations1995Thomas Wölfel, Martina Hauer +8 more
Results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a.
Proceedings of the National Academy of SciencesIdentification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
931 Citations1994Yutaka Kawakami, S Eliyahu +8 more
Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.
The Journal of Experimental MedicineIdentification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
865 Citations1994Yutaka Kawakami, S Eliyahu +6 more
One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis and appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.
ScienceIdentification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
834 Citations1994Andrea L. Cox, Jonathan Skipper +7 more
Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested.
ImmunityCharacterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
772 Citations1997Hideyuki Ikeda, Bernard Lethé +9 more
CTL, active against tumor cells showing partial HLA loss, may constitute an intermediate line of anti-tumor defense between the CTL, which recognizes highly specific tumor antigens, and the NK cells, which recognize HLA Loss variants.
The Journal of Experimental MedicineHuman gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.
765 Citations1994Béatrice Gaugler, Benoı̂t Van den Eynde +7 more
It is shown here that antigen MZ2-D, which is present on the same tumor, is encoded by another member of the MAGE gene family named MAGE-3, which may have a wide applicability for specific immunotherapy of melanoma patients.
Immunology TodayImplications for immunosurveillance of altered HLA class I phenotypes in human tumours
760 Citations1997Federico Garrido, Francisco Ruiz‐Cabello +5 more
Altered HLA class I tumour phenotypes are analyzed in detail, indicating their potential relevance for implementation of immunotherapeutic protocols and strategies to overcome tumour escape mechanisms.
The Journal of Experimental MedicineA nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
694 Citations1992Catia Traversari, Pierre van der Bruggen +7 more
It is shown that CTL directed against this antigen, which was named MZ2-E, recognize a nonapeptide encoded by the third exon of gene MAGE-1, which opens the possibility of immunizing HLA-A1 patients whose tumor expresses Mage-1 either with the antigenic peptide or with autologous antigen-presenting cells pulsed with the peptide.
ImmunogeneticsStructure, chromosomal localization, and expression of 12 genes of the MAGE family
592 Citations1994Etienne De Plaen, Catia Traversari +13 more
Six genes of the MAGE family including MAGE-1 were found to be expressed at a high level in a number of tumors of various histological types and none was expressed in a large panel of healthy tissues, with the exception of testis and placenta.
ImmunityBAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
590 Citations1995Pascale Boël, Claude Wildmann +6 more
The identification of a new gene that codes for a putative protein of 43 aa and seems to belong to a family of several genes, which may prove useful for cancer immunotherapy.
The Journal of Experimental MedicineA new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
575 Citations1995Benoı̂t Van den Eynde, Olivier Peeters +4 more
It is reported here the identification of the gene coding for MZ2-F, another antigen recognized by autologous CTL on Mz2-MEL cells.
Proceedings of the National Academy of SciencesThe activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
548 Citations1996Charles De Smet, Olivier De Backer +4 more
It is concluded that the activation of MAGE-1 in cancer cells is due to the demethylation of the promoter, a consequence of a genome-wide dem methylation process that occurs in many cancers and is correlated with tumor progression.
The Journal of Experimental MedicineA mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
548 Citations1996Paul F. Robbins, Mona El‐Gamil +5 more
The isolation of a cDNA clone encoding beta- catenin was reported, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888, indicating that this represented a unique mutation in this patient's melanoma.
The Journal of Experimental MedicineIdentification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
542 Citations1995Bryan Fisk, Tana Blevins +2 more
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on Her-2 recognized by ovarian tumor-reactive CTL.
The Journal of ImmunologyRecognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
541 Citations1995Yutaka Kawakami, S Eliyahu +8 more
Four of ten HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag.
The LancetA recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
529 Citations1996Leszek K. Borysiewicz, Alison Fiander +11 more
Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.
JNCI Journal of the National Cancer InstituteGeneration of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine
498 Citations1995Kwong-Yok Tsang, S Zaremba +4 more
This study demonstrates for the first time the ability to generate a human cytolytic T- cell response to specific epitopes of CEA in the context of major histocompatibility complex for T-cell-mediated lysis.
BloodTumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial
454 Citations1997Frank J. Hsu, Clemens B. Caspar +6 more
This study confirms an earlier report that patients with B-cell lymphoma can be induced to make a specific immune response against the Ig expressed by their own tumor and shows that the ability to make such an immune response is correlated with a more favorable clinical outcome.
Proceedings of the National Academy of SciencesA mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
421 Citations1995Pierre G. Coulie, Frédéric Lehmann +5 more
An antigen recognized on a human melanoma by autologous cytolytic T lymphocytes is identified, and the sequence coding for the antigenic peptide is located across an exon-intron junction, suggesting that the T-cell-mediated surveillance of the integrity of the genome may extend to some intronic regions.
European Journal of ImmunologyTwo tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes
414 Citations1994Thomas Wölfel, Aline Van Pel +5 more
It is shown that one of these CTL clones recognizes a peptide encoded by the first nine amino acids of the putative signal sequence of tyrosinase.
The Journal of Experimental MedicineAn HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
409 Citations1996Jonathan Skipper, Ronald C. Hendrickson +10 more
The natural peptide target of a CTL clone that recognizes the tyrosinase gene product on melanoma cells is identified and the first demonstration of posttranslational modification of a naturally processed class I-associated peptide is demonstrated.
The Journal of Experimental MedicineIdentification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
406 Citations1997Matthew B. Bloom, Donna Perry-Lalley +5 more
A normal tissue differentiation antigen, tyrosinaserelated protein 2 (TRP-2), expressed by the murine B16 melanoma is identified and a CTL line raised from splenocytes by repeated stimulation in vitro with this peptide could recognize B16 tumor and was therapeutic against 3-d-old established pulmonary metastases.
Proceedings of the National Academy of SciencesThe immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
396 Citations1996Alex Y. Huang, Pamela H. Gulden +10 more
Adoptive transfer with CTL lines specific for this antigen demonstrated that this epitope represents a potent tumor rejection antigen, providing evidence for a unique class of shared immunodominant tumor associated antigens as targets for antitumor immunity.
The Journal of ImmunologyHuman CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
386 Citations1995Maaike E. Ressing, Alessandro Sette +8 more
In mice, the outgrowth of a lethal dose of HPV16-induced tumor cells has been prevented by vaccination with a CTL epitope encoded by HPV16 E7, indicating the feasibility of peptide immunization to obtain antitumor CTL responses.
European Journal of ImmunologyA peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3
370 Citations1994Pierre van der Bruggen, Judy Bastin +7 more
It is reported that the MAGE‐3 gene also codes for another antigenic peptide that is recognized by CTL restricted by HLA‐A2, and the proportion of melanoma tumors expressing this antigen should be approximately 32 % in Caucasian populations.
Journal of ImmunotherapyVitiligo in Patients with Melanoma
334 Citations1996Steven A. Rosenberg, Donald E. White
Patients with metastatic renal cell cancer and metastatic melanoma treated with high-dose interleukin-2-based immunotherapy were prospectively evaluated for the development of vitiligo, providing further evidence that the presence of a growing melanoma can sensitize patients to melanocyte-differentiation antigens.
Scienceβ-Catenin as Oncogene--The Smoking Gun
325 Citations1997Mark Peifer
The protein β-catenin, previously known to be associated with the colon-cancer-causing adenomatous polyposis coli protein, is shown to be an oncogene in its own right.
Proceedings of the National Academy of SciencesInduction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
325 Citations1995Bijay Mukherji, Nitya G. Chakraborty +8 more
Analyses of the nature of the in vivo host immune response to the vaccine revealed that the peptide-pulsed APCs are capable of inducing autologous melanoma-reactive and the nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic disease sites.
The Journal of Experimental MedicineA CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
317 Citations1997Susanna Mandruzzato, Francis Brasseur +3 more
The identification of an antigen recognized by autologous cytolytic T lymphocytes on a human squamous cell carcinoma of the oral cavity is reported, encoded by a mutated form of the CASP-8 gene, suggesting that a significant fraction of the point mutations generating a tumor antigen also play a role in the tumoral transformation or progression.
Proceedings of the National Academy of SciencesInduction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.
309 Citations1994Esteban Celis, Van Tsai +7 more
The nine-residue epitope is identified, derived from the product of the tumor-associated gene MAGE-3, which has the capacity to induce in vitro CTLs that kill melanoma and other tumor cell lines.
CellEradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
300 Citations1989W. Martin Kast, Rienk Offringa +5 more
The data show an important role for CTLs directed against a viral nuclear oncogene product in tumor eradication, and long-term "memory" persists in treated nude mice months after tumor regression.
The Journal of Experimental MedicineThe gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
299 Citations1991B. Van den Eynde, Bernard Lethé +3 more
It is concluded that major tumor rejection antigens of P815 are encoded by a gene showing little or no expression in most normal cells of adult mice, which is unrelated to three previously isolated genes coding for tum-antigens.
International Journal of CancerGranulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo
296 Citations1996Elke J�ger, Mark Ringhoffer +8 more
It is concluded that systemic GM‐CSF enhances immune responses to melanoma‐associated peptides and supports CTL‐mediated tumor rejection in vivo.
PubMedEnhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
277 Citations1997Janice N. Cormier, Michael L. Salgaller +6 more
Although the enhancement of CTL reactivity did not achieve tumor regression, it is possible that the use of recombinant immunogens with increased immunomodulatory capabilities in future clinical trials could reach the threshold of C TL activation necessary for tumor regression.
The Journal of Experimental MedicineIdentification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
276 Citations1996Rongfu Wang, Ettore Appella +3 more
TRP-2 was identified as a second tumor antigen recognized by a HLA-A31– restricted CTL clone derived from the TIL586 cell line, which was only expressed in melanoma, melanocytes, and retina, but not in other human tissues tested.
JNCI Journal of the National Cancer InstituteIn Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen
264 Citations1997Pierpaolo Correale, Carol Nieroda +5 more
These studies form a rational basis for the use of PSA peptides or recombinant vectors encoding PSA in the development of anticancer vaccine immunotherapy protocols for patients with prostate cancer.
The Journal of Experimental MedicineUtilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
258 Citations1996R F Wang, Maria R. Parkhurst +3 more
It is reported that an antigenic peptide, MSLQRQFLR, recognized by TIL586 was not derived from the normal gp75 protein, but resulted from translation of an alternative open reading frame of the same gene.
The Journal of Experimental MedicineMelanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
257 Citations1996Suzanne L. Topalian, Monica I. Gonzales +6 more
Tyrosinase provides a model for anti-melanoma vaccines in which a single molecule can generate multivalent immunization incorporating both CD4+ and CD8+ T cell responses.
NatureCTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
253 Citations1994Ofer Mandelboim, Gideon Berke +4 more
This work uses total acid extraction and repeated fractionation to isolate and sequence Lewis lung carcinoma (3LL)-specific pep-tide(s), which shows sequence homology to the connexin 37 protein.
ImmunityA unique tumor antigen produced by a single amino acid substitution
237 Citations1995Paul A. Monach, Stephen C. Meredith +2 more
Results indicate that this unique tumor antigen is derived from a single amino acid substitution in a cellular protein, similar to that in ribosomal protein L9.
The Journal of Experimental MedicineA peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
232 Citations1996Yannick Guilloux, Sophie Lucas +8 more
The results suggest that a promoter located near the end of the relevant intron is activated in melanoma cells, resulting in the production of an mRNA coding for the antigen.
European Journal of ImmunologyAutologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601
231 Citations1994Pierre van der Bruggen, Jean‐Pierre Szikora +5 more
The identification of a gene, named MAGE‐1, which codes for antigen MZ2‐E which is presented by HLA‐A1 is reported and the range of tumor patients who could be eligible for immunization against MAGE antigens is extended.
PubMedIdentification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.
224 Citations1995Koichi Takahashi, Shigeki Shichijo +3 more
MAGE proteins are normal tissue antigens compartmentalized in particular testicular cells playing an important role in the early phase of the spermatogenesis.
PubMedImmunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
211 Citations1996Michael L. Salgaller, Francesco M. Marincola +2 more
It is demonstrated that immunization with a peptide derived from a tumor-associated protein such as gp100 can provoke a measurable antitumor immune response in cancer patients.
The Journal of Experimental MedicineHuman T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.
208 Citations1991Steffen Jung, H J Schluesener
It is shown here that human CD4+ T cells specifically recognize the mutated protein sequence and can be generated as antigen-specific T lymphocyte lines and offers new perspectives for specific immunotherapy of human malignancies and even precancerous lesions.
The Journal of Experimental MedicineMass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
204 Citations1995Chiara Castelli, Walter J. Storkus +7 more
P939 represents a good candidate for the development of peptide-based immunotherapies for the treatment of patients with melanoma and is coordinately recognized by a CTL clone obtained by limiting dilution from the peripheral blood of an HLA- A2+ melanoma patient.
BloodRecognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
194 Citations1996GJ Bosch, AM Joosten +3 more
It is shown that in vitro immunization of human T cells with a 17 amino acid peptide representing the p210BCR-ABL fusion region resulted in peptide specific CD4+ T-cell lines designated P4, P6, and P7, which indicates that oncoprotein p210b3a2 can be degraded and processed for presentation by MHC class II molecules at the surface of leukemic cells.
The Journal of ImmunologyIdentification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
184 Citations1997Van Tsai, Scott Southwood +6 more
The gp100 melanoma-associated tumor Ag was selected as a model system to study the diversity of human antitumor cytotoxic T cell responses and the immunologic potential of a given tumor-associated Ag and its relevance for the design of effective immune-based therapies is discussed.
ImmunogeneticsA new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma
179 Citations1996Béatrice Gaugler, Nathalie Brouwenstijn +7 more
The cloning of a gene that codes for an antigen recognized by autologous CTL on a human renal carcinoma cell line, encoded by a new gene that is named RAGE1 is reported, which represents the first identification of an antigen recognizing by autologueous C TL on a renal tumor.
The Journal of ImmunologyTumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
179 Citations1993Keith R. Jerome, Nieves Doménech +1 more
Results demonstrate that transfection of autologous or allogeneic B cells with mucin confers upon them tumor Ag-presenting ability as well as susceptibility to lysis by mucin-specific CTL.
Proceedings of the National Academy of SciencesA mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
172 Citations1994Yuji Noguchi, Yu‐Hsien Chen +1 more
The T-cell response to mutated and normal p53 products of BALB/c-derived Meth A sarcoma was analyzed and the specificity of 234 CM-induced CD4+ T cells for 234-region peptides was broader than the reactivity of 234CM-reactive cytotoxic T cells.
The Journal of Experimental MedicineMelanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
171 Citations1993Andrea Anichini, C Maccalli +6 more
Data indicate that tissue-related antigens can be expressed on normal and neoplastic cells of the melanocyte lineage and can be recognized in association with HLA-A2 by CTL clones from melanoma patients.
Nature MedicineBreast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells
164 Citations1996Claude Gimmi, Briggs Morrison +10 more
It is shown that human breast cancer cell lines fail to present alloantigen and the hypothesis that DF3/MUC1 may contribute to the paucity of clinically significant anticarcinoma–specific immune responses is supported.
The Journal of ImmunologyIdentification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
164 Citations1995Xiaojun Kang, Yutaka Kawakami +7 more
It is demonstrated that tumor-infiltrating lymphocytes (TIL) from melanoma patient 1413 recognize a tumor Ag, tyrosinase, in the context of HLA-A24, which represents a reagent that may be used to generate melanoma-specific T cells for adoptive immunotherapy, as well as in peptide vaccines for HLA -A24+ melanoma patients.
Proceedings of the National Academy of SciencesSpontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
152 Citations1996Mads A. Røpke, Jesper Hald +9 more
A cytotoxic T lymphocyte clone generated in vitro from the peripheral blood of a healthy HLA-A2-positive individual against a synthetic p53 protein-derived wild-type peptide was shown to kill squamous carcinoma cell lines derived from two head and neck carcinomas in a L9V/HLA-A 2 specific and restricted fashion.
PubMedEnhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
151 Citations1996Xueyou Hu, Nitya G. Chakraborty +4 more
In vitro stimulation of the postimmunization peripheral blood lymphocytes with the MAGE-1 nonapeptide-loaded antigen presenting cell and interleukin-2 leads to significant expansion of peptide-specific and autologous melanoma-reactive CTL response.
The Journal of Experimental MedicineThe Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68
146 Citations1997Purnima Dubey, Ronald C. Hendrickson +7 more
The results are consistent with mutant p68 being responsible for rejection of the tumor and several functions of p68, which include nucleolar assembly and inhibition of DNA unwinding, may be mediated through its IQ domain, which was altered by the mutation.
The Journal of Experimental MedicineA mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.
143 Citations1996Daniel Brändle, F. Brasseur +3 more
The characterization of an antigen recognized on a renal cell carcinoma by autologous CTL clones is described, encoded by the HLA-A2 gene present in the tumor cells, which shows that HLA class I molecules carrying a tumor-specific mutation can be involved in the recognition of tumor cells by autOLOGOUS CTL.
The Journal of ImmunologyCloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
141 Citations1995Paul F. Robbins, Mona El‐Gamil +7 more
The cloning of a tumor Ag recognized by T cells from melanoma patient 888 is reported, report the role of tumor-specific T cells in mediating the regression of metastatic melanoma has been suggested by the clinical response of patients to treatment with tumor-infiltrating lymphocytes (TIL).
European Journal of ImmunologyA tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
135 Citations1996Vincent Brichard, Jean Herman +6 more
The human tyrosinase gene has been reported previously to code for two distinct antigens recognized on HLA‐A2 melanoma cells by autologous cytolytic T lymphocytes by stimulating lymphocytes of melanoma patient MZ2 with a subclone of the tumor cell line of this patient, and a CTL clone was obtained which recognized tumor cells expressing tyrosInase and HLA•B*4402.
International Journal of CancerIdentification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line
128 Citations1995Alexander B. H. Barker, Marco W.J. Schreurs +5 more
It is demonstrated that the oligoclonal HLA‐A2.1‐restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gpl00 protein, which is an attractive target antigen in the development of immuno‐therapeutic protocols against melanoma.
BloodTumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
127 Citations1996Edward L. Nelson, M Kellis +5 more
Measurement of CTLp frequencies are relevant to the clinical evaluation of human tumor vaccines and suggests that cell-mediated cytolytic immune responses may be an important determinant of vaccine efficacy.
Human ImmunologyIdentification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8
105 Citations1997Joseph Lustgarten, Matthias Theobald +6 more
Several Her-2/neu peptides previously reported to be Immunogenic for human CTL were found not to be immunogenic in transgenic mice, and the basis for these discrepancies is discussed.
ImmunogeneticsA peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
104 Citations1996Jean Herman, Pierre van der Bruggen +7 more
It is shown that MAGE3 also codes for a peptide that is presented to CTL by HLA-1344, which should amount to approximately 17% in the Caucasian population, since 24% of individuals carry theHLA-B44 allele and 76% of these tumors express MAGE2.
American Journal Of Reproductive ImmunologyDistribution of Human Leukocyte Antigen‐ABC and ‐D/DR Antigens in the Unfixed Human Testis
103 Citations1988Gilbert G. Haas, Osmond J. D’Cruz +1 more
Findings indicate that human testicular germ cells express minimal or no MHC antigens.
The Journal of ImmunologyShared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
103 Citations1996Jonathan Skipper, D J Kittlesen +7 more
Findings suggest that cellular immune responses directed against multiple shared melanoma epitopes exist in the 20 to 25% of melanoma patients who express HLA-A3 and that immunotherapy directed against Pmel-17/gp100 and other shared melan cancer Ags may be useful in a large subset of these patients.
European Journal of ImmunologyMouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide
101 Citations1992Bernard Lethé, Benoı̂t Van den Eynde +3 more
The Journal of Experimental MedicineIdentification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
93 Citations1994Akiko Uenaka, Toshiro Ono +4 more
This work established bulk and cloned cytotoxic T lymphocyte lines from regressor (BALB/c x C57BL/6)F1 (CB6F1) spleen cells that recognized RL male 1 specifically and obtained antigen peptide recognized by CTL from RLmale 1 by acid extraction.
TransplantationHLA ANTIGENS IN OCULAR TISSUES
84 Citations1988David Abi‐Hanna, Denis Wakefield +1 more
The majority of ocular cells were found not to express class I or class II HLA antigens, with the exception of the blood vessel endothelium, which was uniformly class I—positive.
Cancer Immunology ImmunotherapyMaking the most of mucin: a novel target for tumor immunotherapy
83 Citations1996Simon M. Barratt‐Boyes
MUC-1 mucin has many characteristics of the ideal tumor-associated antigen, and the understanding of the unique mechanism of mucin recognition on tumors and the appropriate vaccine designs to target this antigen is now advanced.
CellRetrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo
82 Citations1987Fernando Plata, Pierre Langlade‐Demoyen +3 more
The results show that class I H-2 transplantation antigens have a directive influence in determining the antigenicity of proteins encoded by the gag and env MuLV genes.
The Journal of Experimental MedicineLysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
82 Citations1994David Peace, Jerry W. Smith +5 more
The ras peptide-induced CTL specifically lysed syngeneic fibroblasts transformed by an activated ras gene encoding oncogenic p21ras protein containing the same single amino acid substitution can serve as a tumor-specific antigen.
The Journal of Experimental MedicineIdentification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.
81 Citations1993J Skipper, Hans J. Stauss
The murine data raise the possibility of exploiting Ras-specific CTL for targeted immunotherapy of certain human cancers, using recombinant vaccinia viruses expressing these proteins.
Annals of SurgeryExpression of MAGE Genes in Human Colorectal Carcinoma
79 Citations1996Masaki Mori, Hiroshi Inoue +9 more
The MAGE genes were expressed exclusively in tumor tissues of one third of patients with colorectal carcinoma, and the identification of such tumor rejection antigens is considered to uncover a new possibility for the specific immunotherapy of colorective carcinoma.
International Journal of CancerThe expression of mouse geneP1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen
74 Citations1997Catherine Uyttenhove, Catherine Godfraind +8 more
The results obtained in mice with antigen P815AB suggest that immunization of human males with such antigens will not generate autoimmune side‐effects, and the absence of MHC class‐1 molecules on spermatogonia provides a plausible explanation for placental protection, although other mechanisms may also play a role.
The Journal of Experimental MedicineFBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.
72 Citations1989J Klarnet, D E Kern +4 more
In a Friend retrovirus-induced tumor model in which tumor rejection can be mediated by either CTL or Th, antigens derived from discrete retroviral proteins are predominantly responsible for activation of each T cell subset.
Cancer Immunology ImmunotherapyCarcinoembryonic antigen as a target for cancer vaccines
66 Citations1996James W. Hodge, Jeffrey Schlom
The vaccine approach to cancer therapy is still in the early stages, and immunotherapy with these CEA cancer vaccines may prove most effective in the adjuvant setting, where disease has been controlled or stabilized with conventional therapies.
The Journal of ImmunologyA synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein
61 Citations1996Astrid M. Dahl, Peter C. L. Beverley +1 more
The data show the normal T cell repertoire contains small numbers of potentially autoreactive CTL, which may lead to beneficial autoimmunity against tumors, but, equally, it may be the basis of detrimental autoimmune diseases.
European Journal of ImmunologyIdentification of overlapping epitopes in mutant <i>ras</i> oncogene peptides that activate CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses
60 Citations1996Scott I. Abrams, Stephen F. Stanziale +3 more
It is demonstrated that mutant ras p21 at codon 12 (Gly → Val) contained a peptide sequence which exhibited specific functional binding to a murine MHC class I molecule, which was immunogenic for the production of antigen‐specific CD8+ CTL, which lysed in vitro a syngeneic tumor cell line harboring the mutant K‐ras oncogene.
HepatologyHigh frequency of the MAGE-1 gene expression in hepatocellular carcinoma
57 Citations1996Nami Yamashita
Journal of Orthopaedic Research®Expression of MAGE genes in osteosarcoma
56 Citations1997Takao Sudo, Terukazu Kuramoto +3 more
The results suggest that MAGE tumor‐rejection antigens are expressed in substantial numbers of osteosarcomas in a major histocompatibility class‐I‐restricted manner.
VirologyClustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen
55 Citations1988Yuetsu Tanaka, Mary J. Tevethia +3 more
The results indicate that the antigenic sites in the amino terminal half of SV40 T antigen are tightly clustered between amino acids 193 and 271 and most probably between 193 and 228.
International Journal of CancerExpression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma
51 Citations1996Maria Valeria Corrias, Paola Scaruffi +4 more
Investigation of the expression of MAGE, MAGE‐3 and MART‐1 in neuroblastoma cell lines and tumor masses found no correlation was found between MAGE gene expression and clinical stage, event‐free survival and presence or absence of N‐myc amplification.
International Journal of CancerInfrequent expression of the MAGE gene family in uveal melanomas
51 Citations1996Kevin Mulcahy, Donata Rimoldi +11 more
The data suggest that, unlike cutaneous melanomas, uveal melanomas may not be suitable candidates for MAGE‐peptide immunotherapy, and pilot clinical trials with these peptides are currently in progress.
International Journal of CancerMethylated CpG points identified withinMAGE-1 promoter are involved in gene repression
49 Citations1996Alfonso Serrano, Ángel M. García‐Lora +3 more
Using methylation‐sensitive restriction analysis followed by polymerase chain reaction (PCR), an inverse correlation between methylation of the MAGE‐1 B′B region and MAGES‐1 expression is found.
European Journal of ImmunologyT cells recognize the VH complementarity‐determining region 3 of the idiotypic protein of B cell non‐Hodgkin's lymphoma
43 Citations1997Yue‐Jin Wen, Seah H. Lim
It is demonstrated that autologous T cells possessing both CD4+ and CD8+ phenotypes could be propagated and presensitized with the specific peptide in a major histocompatibility complex‐dependent manner and these CDR3 peptide‐primed T cells were also able to kill autOLOGous lymphoma cells.
International Journal of CancerFine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-mhc binding
43 Citations1991W. Martin Kast, Cornelis J.M. Melief
It is shown here that flanking an 8 mer aa sequence, originally described by us as the minimal epitope recognized by CTL, 2 additional aa are important for MHC binding, which leads to the conclusion that this 10‐mer peptide is optimal for M HC binding and T‐cell recognition.
European Journal of ImmunologyPeptide‐specific activation of cytolytic CD4<sup>+</sup> T lymphocytes against tumor cells bearing mutated epitopes of K‐<i>ras</i> p21
43 Citations1995Scott I. Abrams, Mark J. Dobrzanski +6 more
It is demonstrated that peptide immunization produced a CD4+ Th1 response that specifically recognized tumor cells expressing endogenous activated K‐ras epitopes, which may have implications for the development of peptide‐based active immunotherapies.
European Journal of ImmunologyAn intracisternal A‐particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia
38 Citations1994V de Bergeyck, Etienne De Plaen +3 more
The gene coding for the antigen recognized by one of these CTL clones is the gag gene of an endogenous defective retrovirus that belongs to the intracisternal A particle (IAP) family.
International Journal of CancerMAGE-1 andMAGE-3 or-6 expression in neuroblastoma-related pediatric solid tumors
35 Citations1996Hiroyuki Ishida, Takafumi Matsumura +4 more
The results may suggest that NB cells silent for the expression of MAGE genes escape from the host anti‐tumor immune response and consequently retain a growth advantage and could be reliable candidates for immunotherapy targeted towards MAGE gene products.
PubMedExpression of MAGE genes in esophageal squamous-cell carcinoma.
27 Citations1997Véronique Quillien, Jean‐Luc Raoul +4 more
Owing to the high incidence of MAGE gene expression in esophageal squamous-cell carcinoma, a large proportion of patients could be suitable candidates for immune therapies involving tumor-specific antigens encoded by MAGE genes.
PubMedRejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
26 Citations1995Hisashi Wada, Mitsutoshi Matsuo +4 more
The findings show that the molecular alteration of AKT protein by insertion of MuLV LTR is the mechanism for creating rejection antigen peptides derived from the untranslated region of the akt proto-oncogene.
Journal of Surgical OncologyMelanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: Correlation with stage of disease
23 Citations1997Mitsuo Katano, Mitsunari Nakamura +2 more
A human melanoma antigen‐encoding gene‐1, MAGE‐1 gene, may be linked to the neoplastic transformation and this association with human gastric carcinomas is extended.
International Journal of CancerDetection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma
22 Citations1997Osamu Iwamoto, Yumiko Nagao +4 more
It is indicated that MAGE‐4 protein is detectable in sera of a significant number of HN‐SCC patients, and that serum MAGE'4 protein might be a useful tumor marker to monitor the recurrence of MAGE•4‐positive HN-SCC.
International Journal of CancerMAGE-1 gene is expressed in T-cell leukemia
20 Citations1996S Schichijo, Kimitaka Sagawa +3 more
The MAGE-1 gene is preferentially expressed in T-cell leukemia, a family of 12 closely related MAGE genes located on chromosome X, and cases that were not previously reported were found to be identical to other solid cancers.
…